Gilead's quarterly dividend keeps growing and its HIV cash machine runs hot, but the whole enterprise depends on a single blockbuster drug with a patent expiration already penciled onto a calendar a decade out.…
Both Intuitive Surgical and Stryker just posted their fifth straight earnings beat, and Wall Street is cheering for both. But a structural difference buried inside their business models quietly separates a compounder from a…
UiPath stock is cratering despite beating Wall Street's revenue target, and the reason sitting inside the forward guidance explains why investors who rode a 29% rally into earnings are now racing for the exit.
Qualcomm has lost nearly a third of its value while its semiconductor peers surged, leaving one Wall Street analyst staking a reputation on a price target that towers over every other major forecast in…
Trump threatened to cut off trade with deficit countries if the Fed refuses to slash rates, citing a Supreme Court ruling that actually went against him, while his own Fed chair spent the previous…
Warren Buffett refuses to pay a dividend, yet one ETF promises investors a 15% annual payout built entirely around his portfolio. Understanding where that money actually comes from changes everything about how you should…
High midstream yields look tempting until a payout cut wipes out a year of income, so the real question is not the yield itself but whether the cash flow behind it can actually survive…
Tesla launched the Cybercab without asking a single regulator for permission, and now the federal government wants to know how that was even possible. The answer sits inside a legal gray zone that could…
Chinese rare earth suppliers are quietly refusing U.S. shipments, and one American producer just closed a deal that could position it to fill that gap at the worst possible moment for Beijing's leverage.
AMC's CEO just called out Robinhood by name in a scorching public attack over tokens tied to his company's stock, and the fallout is splitting two of retail's biggest names in opposite directions on…
Not every high-yield asset belongs in a Roth IRA, and parking the wrong one there can saddle the account itself with a surprise tax bill. Knowing which popular income payers to keep out changes…
ARK Invest just loaded up on a rocket company trading at a fraction of SpaceX's valuation, and the timing raises a pointed question about whether the recent selloff is a warning sign or a…
AbbVie's flagship drug is bleeding revenue quarter after quarter, yet the company just handed shareholders another raise. Find out whether the cash machine holding this payout together can survive the patent reckoning already underway.
Bullion pays nothing, but the miners extracting it are funneling billions back to shareholders right now. Five precious-metals producers combine gold's defensive appeal with real dividends and buybacks built on free cash flow that…
Nvidia and Apple took opposite approaches to AI spending in 2026, and both are beating the market anyway. The shared contrarian logic behind their gains challenges everything Wall Street assumed about who gets to…
